| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Survivors | 22 | 2025 | 258 | 5.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 17 | 2026 | 788 | 3.040 |
Why?
|
| Neoplasms, Second Primary | 6 | 2025 | 139 | 2.400 |
Why?
|
| Leukemia, Myeloid, Acute | 13 | 2023 | 552 | 2.390 |
Why?
|
| Neoplasms | 19 | 2025 | 2856 | 2.180 |
Why?
|
| Thyroid Neoplasms | 4 | 2021 | 241 | 1.910 |
Why?
|
| Telomere | 4 | 2016 | 207 | 1.420 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 294 | 1.180 |
Why?
|
| Hodgkin Disease | 4 | 2024 | 305 | 1.150 |
Why?
|
| Telomere Shortening | 2 | 2021 | 34 | 1.100 |
Why?
|
| Child | 54 | 2026 | 25228 | 1.100 |
Why?
|
| Chemical and Drug Induced Liver Injury | 3 | 2026 | 134 | 1.090 |
Why?
|
| Telomerase | 3 | 2020 | 153 | 1.070 |
Why?
|
| Survivorship | 3 | 2024 | 46 | 1.040 |
Why?
|
| Mycoses | 2 | 2021 | 111 | 0.960 |
Why?
|
| Neutropenia | 5 | 2023 | 198 | 0.900 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1309 | 0.880 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 1168 | 0.850 |
Why?
|
| Telomere-Binding Proteins | 3 | 2020 | 44 | 0.830 |
Why?
|
| Adolescent | 37 | 2026 | 20082 | 0.810 |
Why?
|
| Dyskeratosis Congenita | 2 | 2013 | 19 | 0.800 |
Why?
|
| Antineoplastic Agents | 5 | 2026 | 1758 | 0.780 |
Why?
|
| Telomere Homeostasis | 2 | 2020 | 45 | 0.730 |
Why?
|
| Patient Preference | 1 | 2023 | 140 | 0.730 |
Why?
|
| Radiotherapy | 3 | 2021 | 120 | 0.730 |
Why?
|
| Health Equity | 1 | 2023 | 76 | 0.720 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3265 | 0.720 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 102 | 0.710 |
Why?
|
| Frailty | 2 | 2021 | 131 | 0.700 |
Why?
|
| Hyperbilirubinemia | 2 | 2022 | 41 | 0.670 |
Why?
|
| Health Status Disparities | 1 | 2024 | 267 | 0.660 |
Why?
|
| Humans | 70 | 2026 | 127099 | 0.660 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 199 | 0.640 |
Why?
|
| Antifungal Agents | 3 | 2024 | 296 | 0.610 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 258 | 0.610 |
Why?
|
| Internet | 2 | 2022 | 402 | 0.600 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 114 | 0.600 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 124 | 0.600 |
Why?
|
| Young Adult | 20 | 2025 | 9694 | 0.600 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.590 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 124 | 0.560 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 74 | 0.560 |
Why?
|
| Down Syndrome | 1 | 2020 | 200 | 0.550 |
Why?
|
| Caregivers | 1 | 2023 | 561 | 0.550 |
Why?
|
| Long Term Adverse Effects | 1 | 2017 | 13 | 0.550 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 156 | 0.540 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 2747 | 0.530 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 51 | 0.530 |
Why?
|
| Siblings | 3 | 2019 | 202 | 0.530 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 321 | 0.510 |
Why?
|
| Infertility | 1 | 2017 | 77 | 0.500 |
Why?
|
| Genetic Variation | 2 | 2020 | 1508 | 0.500 |
Why?
|
| Leukemia, Myeloid | 1 | 2016 | 79 | 0.500 |
Why?
|
| Cognition Disorders | 1 | 2020 | 542 | 0.500 |
Why?
|
| Child, Preschool | 21 | 2026 | 14423 | 0.490 |
Why?
|
| Female | 40 | 2026 | 68483 | 0.480 |
Why?
|
| Prognosis | 9 | 2025 | 4799 | 0.470 |
Why?
|
| Survivors | 5 | 2024 | 347 | 0.470 |
Why?
|
| Male | 36 | 2026 | 62658 | 0.460 |
Why?
|
| Risk Factors | 16 | 2025 | 10610 | 0.440 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2025 | 52 | 0.430 |
Why?
|
| Neutrophils | 1 | 2016 | 355 | 0.430 |
Why?
|
| Methotrexate | 3 | 2025 | 317 | 0.430 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1561 | 0.420 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2025 | 172 | 0.410 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 45 | 0.400 |
Why?
|
| Anemia, Aplastic | 1 | 2013 | 58 | 0.390 |
Why?
|
| Proportional Hazards Models | 5 | 2023 | 1369 | 0.390 |
Why?
|
| Steroids | 1 | 2013 | 158 | 0.380 |
Why?
|
| Papillomavirus Vaccines | 2 | 2025 | 112 | 0.380 |
Why?
|
| Induction Chemotherapy | 2 | 2025 | 54 | 0.370 |
Why?
|
| Obesity | 3 | 2018 | 2320 | 0.350 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 33 | 0.340 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 252 | 0.340 |
Why?
|
| Case-Control Studies | 5 | 2026 | 3322 | 0.340 |
Why?
|
| Hematology | 1 | 2011 | 40 | 0.330 |
Why?
|
| Incidence | 5 | 2024 | 3259 | 0.330 |
Why?
|
| Cardiomyopathies | 2 | 2025 | 499 | 0.330 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 881 | 0.320 |
Why?
|
| Microcephaly | 1 | 2013 | 344 | 0.320 |
Why?
|
| Adult | 17 | 2025 | 30435 | 0.320 |
Why?
|
| Thrombocytopenia, Neonatal Alloimmune | 1 | 2009 | 2 | 0.310 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 386 | 0.300 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 5148 | 0.300 |
Why?
|
| Wolman Disease | 1 | 2009 | 7 | 0.300 |
Why?
|
| Sterol Esterase | 1 | 2009 | 19 | 0.300 |
Why?
|
| Isoantibodies | 1 | 2009 | 62 | 0.300 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2009 | 78 | 0.300 |
Why?
|
| Cellular Senescence | 1 | 2010 | 197 | 0.290 |
Why?
|
| Retrospective Studies | 16 | 2025 | 17065 | 0.290 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2036 | 0.290 |
Why?
|
| Infant | 14 | 2026 | 12784 | 0.290 |
Why?
|
| Anthracyclines | 3 | 2025 | 43 | 0.280 |
Why?
|
| HLA Antigens | 1 | 2009 | 218 | 0.280 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 629 | 0.260 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1431 | 0.250 |
Why?
|
| Societies, Medical | 1 | 2011 | 761 | 0.250 |
Why?
|
| Texas | 4 | 2023 | 3563 | 0.250 |
Why?
|
| Intellectual Disability | 1 | 2013 | 1048 | 0.240 |
Why?
|
| Electronics | 2 | 2023 | 45 | 0.240 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 117 | 0.240 |
Why?
|
| Connectin | 1 | 2025 | 28 | 0.230 |
Why?
|
| Human Growth Hormone | 1 | 2025 | 67 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1273 | 0.230 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 37 | 0.220 |
Why?
|
| Candida tropicalis | 1 | 2024 | 17 | 0.220 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2025 | 161 | 0.220 |
Why?
|
| Candidiasis, Invasive | 1 | 2024 | 23 | 0.220 |
Why?
|
| Growth Disorders | 1 | 2025 | 181 | 0.220 |
Why?
|
| Medical Oncology | 1 | 2025 | 228 | 0.200 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 490 | 0.200 |
Why?
|
| Body Fluids | 1 | 2023 | 46 | 0.200 |
Why?
|
| Metabolome | 1 | 2025 | 315 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3933 | 0.190 |
Why?
|
| Lipids | 1 | 2026 | 546 | 0.190 |
Why?
|
| Asparaginase | 1 | 2022 | 48 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 45 | 0.190 |
Why?
|
| Metabolomics | 1 | 2025 | 455 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 48 | 0.180 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 50 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 583 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2022 | 136 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2021 | 4972 | 0.170 |
Why?
|
| Middle Aged | 6 | 2023 | 27801 | 0.170 |
Why?
|
| Aftercare | 2 | 2022 | 151 | 0.170 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 140 | 0.170 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 28 | 0.170 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 900 | 0.160 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 33 | 0.160 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 137 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 192 | 0.160 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 1728 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 176 | 0.160 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 165 | 0.160 |
Why?
|
| Poverty | 1 | 2023 | 447 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 123 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 225 | 0.160 |
Why?
|
| Parents | 2 | 2023 | 1076 | 0.150 |
Why?
|
| Infant, Newborn | 6 | 2024 | 8350 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2020 | 135 | 0.150 |
Why?
|
| Fatal Outcome | 2 | 2011 | 359 | 0.150 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 315 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2022 | 321 | 0.150 |
Why?
|
| Introns | 1 | 2020 | 281 | 0.150 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 398 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2025 | 778 | 0.150 |
Why?
|
| Medulloblastoma | 1 | 2022 | 379 | 0.140 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1711 | 0.140 |
Why?
|
| Aging, Premature | 1 | 2018 | 30 | 0.140 |
Why?
|
| Remission Induction | 2 | 2016 | 298 | 0.140 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 10 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2020 | 738 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 189 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 260 | 0.140 |
Why?
|
| Heart Atria | 1 | 2020 | 325 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 249 | 0.140 |
Why?
|
| Sepsis | 1 | 2022 | 494 | 0.140 |
Why?
|
| Stroke Volume | 1 | 2020 | 514 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 576 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 203 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 2586 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 357 | 0.130 |
Why?
|
| Longevity | 1 | 2018 | 154 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2018 | 122 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2018 | 309 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2020 | 395 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 521 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 1399 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 808 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 664 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2020 | 1199 | 0.120 |
Why?
|
| Parent-Child Relations | 1 | 2017 | 254 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 489 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 570 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2025 | 3588 | 0.120 |
Why?
|
| Alleles | 1 | 2020 | 1609 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2018 | 384 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 799 | 0.110 |
Why?
|
| Biopsy | 1 | 2018 | 1237 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 865 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 42 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 42 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1633 | 0.110 |
Why?
|
| Echocardiography | 1 | 2020 | 1115 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 53 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1340 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1054 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 1141 | 0.100 |
Why?
|
| Mutation | 2 | 2020 | 5947 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 540 | 0.100 |
Why?
|
| Pedigree | 2 | 2014 | 1655 | 0.100 |
Why?
|
| Epilepsy | 1 | 2020 | 844 | 0.100 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 143 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 316 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 133 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 348 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 352 | 0.090 |
Why?
|
| Age Distribution | 1 | 2013 | 423 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2018 | 1032 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 669 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2029 | 0.090 |
Why?
|
| Homozygote | 1 | 2013 | 540 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 964 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1387 | 0.080 |
Why?
|
| Glioma | 1 | 2014 | 480 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1498 | 0.080 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2009 | 31 | 0.080 |
Why?
|
| Biomarkers | 2 | 2026 | 3233 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 2233 | 0.070 |
Why?
|
| Liver Failure | 1 | 2009 | 89 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2010 | 438 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2025 | 6242 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 477 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 304 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 1198 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 1235 | 0.060 |
Why?
|
| Cranial Irradiation | 1 | 2025 | 72 | 0.060 |
Why?
|
| Neuroblastoma | 1 | 2010 | 539 | 0.060 |
Why?
|
| Drug Resistance, Fungal | 1 | 2024 | 28 | 0.060 |
Why?
|
| Pediatrics | 2 | 2025 | 1203 | 0.050 |
Why?
|
| Apoptosis | 1 | 2010 | 1825 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 197 | 0.050 |
Why?
|
| Risk | 2 | 2018 | 735 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 1421 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 102 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 40 | 0.050 |
Why?
|
| Machine Learning | 1 | 2025 | 325 | 0.040 |
Why?
|
| Demography | 1 | 2022 | 237 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 823 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 179 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2022 | 229 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2021 | 83 | 0.040 |
Why?
|
| Logistic Models | 1 | 2026 | 1788 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 2799 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4306 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 240 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2022 | 286 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 755 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 40 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 193 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 424 | 0.040 |
Why?
|
| Vaccination | 1 | 2025 | 1004 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 369 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 308 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 775 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1047 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 201 | 0.040 |
Why?
|
| Family | 1 | 2021 | 580 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 438 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2020 | 12567 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 659 | 0.030 |
Why?
|
| Bleomycin | 1 | 2018 | 110 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1108 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 154 | 0.030 |
Why?
|
| United States | 2 | 2025 | 11386 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1206 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 201 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 711 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 175 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1277 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 7395 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 1537 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 552 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 871 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2022 | 781 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 20 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 656 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 1879 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2886 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 2612 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 1651 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 827 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3680 | 0.020 |
Why?
|
| Aged | 2 | 2023 | 20431 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6142 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2048 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 1522 | 0.020 |
Why?
|
| Gangliosides | 1 | 2010 | 66 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1063 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 231 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 283 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2991 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 985 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 219 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1014 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 672 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1231 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 445 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2541 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2397 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 4484 | 0.010 |
Why?
|